Asthma is a common chronic inflammatory disease of the airways which remains uncontrolled despite current therapy for many patients. Asthma is characterised by fluctuating symptoms which include coughing, chest tightness, wheezing and shortness of breath. Genetic and environmental factors contribute to asthma and there are numerous stimuli that can trigger asthma, both atopic (allergic) and non-atopic (non-allergic).
Asthma has no cure, so long-term prevention focuses on avoiding known triggers. Asthma is classified by the frequency and extent of symptoms, the forced expiratory volume in one second (FEV1) and peak expiratory flow rate.
Treatment options for asthma include inhaled corticosteroids (ICS) which can be used alongside long-acting beta 2 agonists (LABA) or antileukotriene agents if the symptoms persist. Short-acting β2-agonist (SABA) as the only treatment is no longer recommended following strong evidence that this increases the risk of severe exacerbations and asthma-related death. Adding any ICS significantly reduces this risk.
To find out more about moderate to severe asthma, visit our dedicated Learning Zone, which contains further information on the causes of asthma and the Global Initiative for Asthma (GINA) recommendations for management.
Featured Learning Zones
This learning zone helps you further your knowledge around moderate and severe asthma and its management. It has been designed to support you in identifying effective approaches to optimise your management strategies, while also updating you about asthma and its treatment landscape.
Related news and insights
Novartis announced that full results from the Phase III IRIDIUM study were published in The Lancet Respiratory Medicine. The primary endpoint results show that once-daily treatment with high- and medium-dose Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) demonstrated statistically significant improvements in lung function compared with once-daily QMF149 (indacaterol acetate and mometasone furoate [IND/MF]).
Novartis announced that full results from the Phase IIIb ARGON study were published online in Respiratory Medicine.
Novartis announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of Enerzair Breezhaler (QVM 149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist (LABA) and a high dose of an inhaled corticosteroid (ICS) who experienced one or more asthma exacerbations in the previous year.
You may be interested in...
ICRMB 2021: 15. International Conference on Reproductive Medicine and Biology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Reproductive Medicine and Biology.
International Conference on Nephrology and Urology
ICNU 2021: 15. International Conference on Nephrology and Urology aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Nephrology and Urology.
18th Meeting of the EAU Section of Oncological Urology
ESOU21 will take place in conjunction with the meeting of the EAU Section of Urological Research (ESUR). Thus it will be an opportunity to have collaborative sessions and knowledge exchange with our colleagues from this prestigious office of the EAU.